Profiling of Invasive Breast Carcinoma Circulating Tumour Cells-Are We Ready for the 'Liquid' Revolution?

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2019 Jan 30

PMID 30691008

Citations 4

Authors

Marcin Braun

Aleksandra Markiewicz

Radzislaw Kordek

Rafal Sadej

Hanna Romanska

Affiliations

Soon will be listed here.

Abstract

As dissemination through blood and lymph is the critical step of the metastatic cascade, circulating tumour cells (CTCs) have attracted wide attention as a potential surrogate marker to monitor progression into metastatic disease and response to therapy. In patients with invasive breast carcinoma (IBC), CTCs are being considered nowadays as a valid counterpart for the assessment of known prognostic and predictive factors. Molecular characterization of CTCs using protein detection, genomic and transcriptomic panels allows to depict IBC biology. Such molecular profiling of circulating cells with increased metastatic abilities appears to be essential, especially after tumour resection, as well as in advanced disseminated disease, when information crucial for identification of therapeutic targets becomes unobtainable from the primary site. If CTCs are truly representative of primary tumours and metastases, characterization of the molecular profile of this easily accessible 'biopsy' might be of prime importance for clinical practice in IBC patients. This review summarizes available data on feasibility and documented benefits of monitoring of essential IBC biological features in CTCs, with special reference to multifactorial proteomic, genomic, and transcriptomic panels of known prognostic or predictive value.

Citing Articles

Circulating Tumor Cells as a Tool to Untangle the Breast Cancer Heterogeneity Issue.

Rossi T, Gallerani G, Martinelli G, Maltoni R, Fabbri F Biomedicines. 2021; 9(9).

PMID: 34572427 PMC: 8466266. DOI: 10.3390/biomedicines9091242.

Functional Genomic Analysis of Breast Cancer Metastasis: Implications for Diagnosis and Therapy.

Yu Z, Song M, Chouchane L, Ma X Cancers (Basel). 2021; 13(13).

PMID: 34208889 PMC: 8268362. DOI: 10.3390/cancers13133276.

Challenges and achievements of liquid biopsy technologies employed in early breast cancer.

Alba-Bernal A, Lavado-Valenzuela R, Dominguez-Recio M, Jimenez-Rodriguez B, Queipo-Ortuno M, Alba E EBioMedicine. 2020; 62:103100.

PMID: 33161226 PMC: 7670097. DOI: 10.1016/j.ebiom.2020.103100.

The Role of Breast Cancer Stem Cells as a Prognostic Marker and a Target to Improve the Efficacy of Breast Cancer Therapy.

Scioli M, Storti G, DAmico F, Gentile P, Fabbri G, Cervelli V Cancers (Basel). 2019; 11(7).

PMID: 31330794 PMC: 6678191. DOI: 10.3390/cancers11071021.

References

Pantel K, Cote R, Fodstad O . Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst. 1999; 91(13):1113-24. DOI: 10.1093/jnci/91.13.1113. View

Thomas P, Kirschmann D, Cerhan J, Folberg R, Seftor E, Sellers T . Association between keratin and vimentin expression, malignant phenotype, and survival in postmenopausal breast cancer patients. Clin Cancer Res. 1999; 5(10):2698-703. View

Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C . TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res. 2000; 6(1):50-6. View

Berns E, Foekens J, Vossen R, Look M, Devilee P, Henzen-Logmans S . Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res. 2000; 60(8):2155-62. View

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

Sorlie T, Perou C, Tibshirani R, Aas T, Geisler S, Johnsen H . Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98(19):10869-74. PMC: 58566. DOI: 10.1073/pnas.191367098. View

J van t Veer L, Dai H, van de Vijver M, He Y, Hart A, Mao M . Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415(6871):530-6. DOI: 10.1038/415530a. View

van de Vijver M, He Y, Vant Veer L, Dai H, Hart A, Voskuil D . A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347(25):1999-2009. DOI: 10.1056/NEJMoa021967. View

Fidler I . The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003; 3(6):453-8. DOI: 10.1038/nrc1098. View

10.

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron J, Nobel A . Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100(14):8418-23. PMC: 166244. DOI: 10.1073/pnas.0932692100. View

11.

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

12.

Allard W, Matera J, Miller M, Repollet M, Connelly M, Rao C . Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004; 10(20):6897-904. DOI: 10.1158/1078-0432.CCR-04-0378. View

13.

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

14.

Meng S, Tripathy D, Frenkel E, Shete S, Naftalis E, Huth J . Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res. 2004; 10(24):8152-62. DOI: 10.1158/1078-0432.CCR-04-1110. View

15.

Braun S, Naume B . Circulating and disseminated tumor cells. J Clin Oncol. 2005; 23(8):1623-6. DOI: 10.1200/JCO.2005.10.073. View

16.

Gould Rothberg B, Bracken M . E-cadherin immunohistochemical expression as a prognostic factor in infiltrating ductal carcinoma of the breast: a systematic review and meta-analysis. Breast Cancer Res Treat. 2006; 100(2):139-48. DOI: 10.1007/s10549-006-9248-2. View

17.

Berns K, Horlings H, Hennessy B, Madiredjo M, Hijmans E, Beelen K . A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007; 12(4):395-402. DOI: 10.1016/j.ccr.2007.08.030. View

18.

Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M . Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol. 2007; 25(33):5194-202. DOI: 10.1200/JCO.2007.11.7762. View

19.

Fehm T, Becker S, Duerr-Stoerzer S, Sotlar K, Mueller V, Wallwiener D . Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res. 2007; 9(5):R74. PMC: 2242672. DOI: 10.1186/bcr1783. View

20.

Wu J, Fackler M, Halushka M, Molavi D, Taylor M, Teo W . Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res. 2008; 14(7):1938-46. PMC: 2965068. DOI: 10.1158/1078-0432.CCR-07-4082. View